Beta-lactamase hydrolysis and inhibition studies of the new 1-carbacephem LY163892.
A novel 1-carbacephem, LY163892, was determined to be more stable to plasmid-mediated beta-lactamases than cefaclor. Chromosomal-mediated Type Ia and IVc enzymes destroyed LY163892 at rates ranging from 16 to 93% that of nitrocefin. LY163892 showed minimal ability to inhibit beta-lactamases other than Type Ia (P99).
D002433:Cefaclor / Q000378:metabolism / Q000494:pharmacology; D002439:Cefotaxime / Q000378:metabolism; D002509:Cephaloridine / Q000378:metabolism; D002511:Cephalosporins / Q000378:metabolism* / Q000494:pharmacology; D006868:Hydrolysis; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000378:metabolism*
D002511:Cephalosporins; D065093:beta-Lactamase Inhibitors; C026739:carbacephems; C054920:loracarbef; D002433:Cefaclor; D001618:beta-Lactamases; C021720:nitrocefin; D002509:Cephaloridine; D002439:Cefotaxime